Review ArticlesThe Genomic and Molecular Pathology of Prostate Cancer Clinical Implications for Diagnosis, Prognosis, and TherapyFaisal, Farzana A. MD*; Lotan, Tamara L. MD*,†,‡Author Information *Brady Urological Institute Departments of †Pathology ‡Oncology, Johns Hopkins University School of Medicine, Baltimore, MD T.L.L.: has received prior research funding from Ventana/Roche and GenomeDx Biosciences and has consulted for Janssen Pharmaceuticals. F.A.F. has no conflicts of interest to disclose. Reprints: Tamara L. Lotan, MD, 1550 Orleans St, CRB2 Room 343, Baltimore, MD 21231 (e-mail: email@example.com). Online date: September 9, 2019 Advances In Anatomic Pathology: January 2020 - Volume 27 - Issue 1 - p 11-19 doi: 10.1097/PAP.0000000000000245 Buy Metrics Abstract Prostate cancer (PCa) is the most common noncutaneous malignancy affecting American men and the second most common cause of cancer death. The traditional risk classification schemes for PCa are limited due to the vast clinical and molecular heterogeneity of the disease. Fortunately, recent advancements in sequencing technologies have provided us with valuable insight into the genomics of PCa. To date, a wide array of recurrent genomic alterations in PCa have been identified. Incorporating these distinct molecular subtypes of PCa into prediction models provides opportunities for improved risk stratification and ultimately better patient outcomes. In this review, we summarize the key molecular subtypes of PCa and focus on those genomic alterations that have clinical implications for diagnosis, prognosis, and therapeutic response. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.